Literature DB >> 15622131

Neurophysiologic studies in Morvan syndrome.

Keith A Josephs1, Michael H Silber, Robert D Fealey, Todd B Nippoldt, Raymond G Auger, Steven Vernino.   

Abstract

This study was conducted to clarify the clinical and neurophysiologic characteristics of patients with Morvan syndrome, and to compare and contrast this syndrome with other forms of autoimmune encephalitis. A retrospective chart review of the clinical features and neurophysiologic studies of two cases of Morvan syndrome seen at the Mayo Clinic was performed. Neurophysiologic studies included polysomnography, comprehensive autonomic testing, MRI, positron emission tomography, EEG, and single-photon emission computed tomography. In two cases of Morvan syndrome, the clinical features, electrophysiologic findings, and immunologic studies (high levels of voltage-gated potassium channel antibodies) were consistent with previously reported findings. Several novel observations were made. Autonomic testing demonstrated peripheral autonomic neuropathy in addition to autonomic hyperactivity. Polysomnography showed complete absence of sleep. Neuroimaging study findings were largely normal. Morvan syndrome is an autoimmune disorder affecting both the peripheral and central nervous system. Neurophysiologic studies demonstrate hyperexcitability of peripheral nerves, autonomic dysfunction, and severe insomnia. The absence of abnormalities on imaging studies suggests that central nervous system symptoms are related to functional rather than structural disruption of neural networks.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15622131     DOI: 10.1097/00004691-200411000-00008

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.177


  22 in total

1.  Hypnotic effects of a novel anti-insomnia formula on Drosophila insomnia model.

Authors:  Chun-Hay Ko; Chi-Man Koon; Siu-Lung Yu; Kwok-Ying Lee; Clara Bik-San Lau; Edwin Ho-Yin Chan; Yun-Kwok Wing; Kwok-Pui Fung; Ping-Chung Leung
Journal:  Chin J Integr Med       Date:  2014-08-26       Impact factor: 1.978

Review 2.  Pathophysiologic mechanisms in REM sleep behavior disorder.

Authors:  Mark W Mahowald; Carlos H Schenck; Michel A Cramer Bornemann
Journal:  Curr Neurol Neurosci Rep       Date:  2007-03       Impact factor: 5.081

Review 3.  Autoimmune channelopathies: well-established and emerging immunotherapy-responsive diseases of the peripheral and central nervous systems.

Authors:  Angela Vincent
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

4.  Chronic pain as a manifestation of potassium channel-complex autoimmunity.

Authors:  Christopher J Klein; Vanda A Lennon; Paula A Aston; Andrew McKeon; Sean J Pittock
Journal:  Neurology       Date:  2012-08-15       Impact factor: 9.910

Review 5.  Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances.

Authors:  Elisabeth P Golden; Steven Vernino
Journal:  Clin Auton Res       Date:  2019-05-15       Impact factor: 4.435

6.  Morvan Syndrome: A Case Report With Patient Narrative and Video.

Authors:  Mark Maskery; Suresh K Chhetri; Rejith Dayanandan; Claire Gall; Hedley C A Emsley
Journal:  Neurohospitalist       Date:  2016-01

Review 7.  Autoimmune and paraneoplastic channelopathies.

Authors:  Steven Vernino
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

8.  Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.

Authors:  Christopher J Klein; Vanda A Lennon; Paula A Aston; Andrew McKeon; Orna O'Toole; Amy Quek; Sean J Pittock
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

Review 9.  REM Sleep Behavior Disorder: Diagnosis, Clinical Implications, and Future Directions.

Authors:  Erik K St Louis; Bradley F Boeve
Journal:  Mayo Clin Proc       Date:  2017-11-01       Impact factor: 7.616

Review 10.  Antibody testing as a diagnostic tool in autonomic disorders.

Authors:  Steven Vernino
Journal:  Clin Auton Res       Date:  2008-08-22       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.